Now available, the Covid-19 BioCard™ is an ultra-rapid antibody screen or confirmatory IVD, for healthcare professionals.
The Bio-Diagnostics BioCard™ was developed in direct response to the COVID-19 pandemic, with research beginning in February 2020 in the UK. The BioCard™ utilises the companies 40 years’ experience in antibody testing and its extensive in vitro diagnosis expertise. The BioCard is CE marked and available for delivery throughout Europe immediately.
Physical adaptations from the established QuickCard technology, combined with specific changes to the Biochemistry of the device, have resulted in a robust, accurate and ultra-rapid IgG antibody test indicative of a COVID-19 specific immune response.
The Covid-19 BioCard™ is a S1 Spike specific IgG Antibody detection platform IVD screen and/or confirmatory method, for the specific detection of circulating IgG Antibodies to the S1 Spike of the SARS-CoV-2 virus. Presence of specific IgG to the S1 portion of the SARS-CoV-2 infection is a marker used as a tool to assist in identifying past SARS-CoV-2 infection given its unique specificity to the SARS-CoV-2 virus.
A positive result demonstrates the presence of a S1 specific Ag for COVID-19, inferring past infection. This test is intended to be used by competently trained healthcare professionals, utilising venous bleed where possible. The validation also included use of finger prick blood draws, which will imminently result in a specific CE marked home bleed kit for limitless testing applications.
Without need for any processor, specialist equipment or wider costs, individual results are available within as little as 5 minutes. All individual tests will complete within 10 minutes and multiple devices can be run concurrently enabling thousands of results to be attained per hour by a small team.
No analyser is required, therefore tests can be performed in clinics, pharmacies and pop-up labs, drive-throughs and other appropriate locations when overseen by healthcare professionals. Where large laboratories suffer bottle necks or require a backup to automation failures, results can be attained on a par with laboratory processors.
The Covid-19 BioCard™ provides a mass screening method with professional quality laboratory results, to differentiate those with Covid-19 specific IgG antibodies from those without. Where best practice is in use and a confirmatory method is required, the Covid-19 BioCard™ is a perfect alternative method to any other.
As the BioCard™ can be readily adapted for the testing of any disease, should Covid-19 mutate and existing methods become obsolete, the technology is continuing to be adapted in parallel to ensure it remains an effective device to combat the global pandemic effectively.
Used responsibly, in combination with other clinical data wherever possible, the BioCard can be used at National and international levels, utilising the results the to help societies and economies recover.
For further information on the Covid-19 BioCard™ please contact us.